Reports
As the novel coronavirus (COVID-19) continues to spread across the world, our analysts are constantly tracking the impact of this rapidly evolving situation on the markets and the consumer purchase behaviours. Thus, our latest estimates and analysis about the current market trends and forecast will exhaustively reflect the effects of this emerging pandemic.
Global Haemato Oncology Testing Market: By Cancer Type: Laeukemia, Lymphoma, Hodgkin Lymphoma, Others; By Technology: PCR, IHC, NGS, Cytogenetics, Others; By Application; Regional Analysis; Historical Market and Forecast (2017-2027); Market Dynamics: SWOT Analysis; Competitive Landscape; Industry Events and Developments
Global Haemato Oncology Testing Market Outlook
The global haemato oncology testing market is forecast to reach USD 4.6 billion by 2026 from USD 1.8 billion in 2020, growing at a CAGR of 17% over the forecast period of 2022-2027.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Haematological malignancies are among the top ten malignant disorders in terms of incidence rate and cause of death in cancer patients. They collectively make up about 9% of all cancer cases diagnosed in a year. Geneticists provide not only diagnostic tests to haemato oncologists, but also key knowledge of cancer genetics that helps the specialists evaluate their patient’s prognosis, select the most appropriate anticancer therapy, and monitor treatment response.
Properties and Applications
Haemato oncology testing is a test that aids in the diagnosis of blood disease (haematology) and cancer (oncology), further supporting the treatment and prevention of the disease, and providing research into them. Haematology-oncology includes diseases such as iron deficiency anaemia, haemophilia, sickle cell disease, thalassemia, leukaemia, and other organ cancers.
The haemato oncology testing industry can be divided based on segments like cancer type, technology, and application.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The industry can be divided based on cancer type as:
- Leukaemia
- Lymphoma
- Hodgkin Lymphoma
- Others
The industry can be divided based on technology as PCR, IHC, NGS, and cytogenetics, among others.
The industry can be broadly categorised based on application into:
- Clinical Laboratories
- Hospitals
- Academic and Research Institutes
- Others
The EMR report looks into the regional markets of haemato oncology testing like North America, Latin America, Europe, the Middle East and Africa, and the Asia Pacific.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Analysis
The global haemato oncology testing market is driven by haematological cancer’s increasing global prevalence, increasing awareness of personalized medicines, and increasing collaborations to develop new assays. On the other hand, it is expected that an uncertain reimbursement scenario will restrict the growth of this market during the forecast period in various regions.
The services segment represents the largest proportion of haemato oncology testing. This is mainly due to the growing prevalence and incidence of leukaemia, non-Hodgkin lymphoma, and cancer of myeloma. In addition, the growing awareness of advanced therapies such as personalized medicine also drives this segment’s growth. The growth in the Asia Pacific market is driven primarily by the large patient population, and a growing focus on expanding in this region will drive the industry growth.
Competitive Landscape
The report presents a detailed analysis of the following key players in the global haemato oncology testing market, looking into their capacity, market shares, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:
- F. Hoffmann-La Roche Ltd. [Roche Holding AG]
- Abbott [NYSE: ABT]
- Qiagen
- Thermo Fisher Scientific Inc.
- Illumina, Inc.
- Bio-Rad Laboratories, Inc.
- MolecularMD [ICON plc]
- ArcherDX, Inc.
- Arup Laboratories
- Asuragen, Inc.
- Others
The EMR report gives an in-depth insight into the industry by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.
| REPORT FEATURES | DETAILS |
|---|---|
| Base Year | 2020 |
| Historical Period | 2017-2021 |
| Forecast Period | 2022-2027 |
| Scope of the Report | Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment- Cancer Type, Technology, Application, Region |
| Breakup by Cancer Type | Leukaemia, Lymphoma, Hodgkin Lymphoma, Others |
| Breakup by Technology | PCR, IHC, NGS, Cytogenetics, Others |
| Breakup by Application | Clinical Laboratories, Hospitals, Academic & Research Institutes, Others |
| Breakup by Region | North America, Europe, Asia Pacific, Latin America, Middle East and Africa |
| Market Dynamics | SWOT, Porter's Five Forces, EMR’s Key Indicators for Price and Demand |
| Competitive Landscape | Market Structure, Company Profiles- Company Overview, Product Portfolio, Demographic Reach and Achievements, Certifications |
| Companies Covered | F. Hoffmann-La Roche Ltd. [Roche Holding AG], Abbott [ABT (NYSE)], Qiagen [QGEN (NYSE)], Thermo Fisher Scientific Inc., Illumina, Inc. [ILMN (NASDAQ)], Bio-Rad Laboratories, Inc. [BIO (NYSE)], MolecularMD [ICON plc], ArcherDX, Inc., Arup Laboratories, Asuragen, Inc., Others |
| Report Price and Purchase Option | Explore our purchase options that are best suited to your resources and industry needs. |
| Delivery Format | Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option. |
*We at Expert Market Research always thrive to give you the latest information. The numbers in the article are only indicative and may be different from the actual report.
1 Preface
2 Report Coverage – Key Segmentation and Scope
3 Report Description
3.1 Market Definition and Outlook
3.2 Properties and Applications
3.3 Market Analysis
3.4 Key Players
4 Key Assumptions
5 Executive Summary
5.1 Overview
5.2 Key Drivers
5.3 Key Developments
5.4 Competitive Structure
5.5 Key Industrial Trends
6 Snapshot
6.1 Global
6.2 Regional
7 Industry Opportunities and Challenges
8 Global Haemato Oncology Testing Market Analysis
8.1 Key Industry Highlights
8.2 Global Haemato Oncology Testing Historical Market (2017-2021)
8.3 Global Haemato Oncology Testing Market Forecast (2022-2027)
8.4 Global Haemato Oncology Testing Market by Cancer Type
8.4.1 Laeukemia
8.4.1.1 Market Share
8.4.1.2 Historical Trend (2017-2021)
8.4.1.3 Forecast Trend (2022-2027)
8.4.2 Lymphoma
8.4.2.1 Market Share
8.4.2.2 Historical Trend (2017-2021)
8.4.2.3 Forecast Trend (2022-2027)
8.4.3 Hodgkin Lymphoma
8.4.3.1 Market Share
8.4.3.2 Historical Trend (2017-2021)
8.4.3.3 Forecast Trend (2022-2027)
8.4.4 Others
8.5 Global Haemato Oncology Testing Market by Technology
8.5.1 PCR
8.5.1.1 Market Share
8.5.1.2 Historical Trend (2017-2021)
8.5.1.3 Forecast Trend (2022-2027)
8.5.2 IHC
8.5.2.1 Market Share
8.5.2.2 Historical Trend (2017-2021)
8.5.2.3 Forecast Trend (2022-2027)
8.5.3 NGS
8.5.3.1 Market Share
8.5.3.2 Historical Trend (2017-2021)
8.5.3.3 Forecast Trend (2022-2027)
8.5.4 Cytogenetics
8.5.4.1 Market Share
8.5.4.2 Historical Trend (2017-2021)
8.5.4.3 Forecast Trend (2022-2027)
8.5.5 Others
8.6 Global Haemato Oncology Testing Market by Application
8.6.1 Clinical Laboratories
8.6.1.1 Market Share
8.6.1.2 Historical Trend (2017-2021)
8.6.1.3 Forecast Trend (2022-2027)
8.6.2 Hospitals
8.6.2.1 Market Share
8.6.2.2 Historical Trend (2017-2021)
8.6.2.3 Forecast Trend (2022-2027)
8.6.3 Academic and Research Institutes
8.6.3.1 Market Share
8.6.3.2 Historical Trend (2017-2021)
8.6.3.3 Forecast Trend (2022-2027)
8.6.4 Others
8.7 Global Haemato Oncology Testing Market by Region
8.7.1 Market Share
8.7.1.1 North America
8.7.1.2 Europe
8.7.1.3 Asia Pacific
8.7.1.4 Latin America
8.7.1.5 Middle East and Africa
9 Regional Analysis
9.1 North America
9.1.1 Historical Trend (2017-2021)
9.1.2 Forecast Trend (2022-2027)
9.1.3 Breakup by Country
9.1.3.1 United States of America
9.1.3.2 Canada
9.2 Europe
9.2.1 Historical Trend (2017-2021)
9.2.2 Forecast Trend (2022-2027)
9.2.3 Breakup by Country
9.2.3.1 United Kingdom
9.2.3.2 Germany
9.2.3.3 France
9.2.3.4 Italy
9.2.3.5 Others
9.3 Asia Pacific
9.3.1 Historical Trend (2017-2021)
9.3.2 Forecast Trend (2022-2027)
9.3.3 Breakup by Country
9.3.3.1 China
9.3.3.2 Japan
9.3.3.3 India
9.3.3.4 ASEAN
9.3.3.5 Australia
9.3.3.6 Others
9.4 Latin America
9.4.1 Historical Trend (2017-2021)
9.4.2 Forecast Trend (2022-2027)
9.4.3 Breakup by Country
9.4.3.1 Brazil
9.4.3.2 Argentina
9.4.3.3 Mexico
9.4.3.4 Others
9.5 Middle East and Africa
9.5.1 Historical Trend (2017-2021)
9.5.2 Forecast Trend (2022-2027)
9.5.3 Breakup by Country
9.5.3.1 Saudi Arabia
9.5.3.2 United Arab Emirates
9.5.3.3 Nigeria
9.5.3.4 South Africa
9.5.3.5 Others
10 Market Dynamics
10.1 SWOT Analysis
10.1.1 Strengths
10.1.2 Weaknesses
10.1.3 Opportunities
10.1.4 Threats
10.2 Porter’s Five Forces Analysis
10.2.1 Supplier’s Power
10.2.2 Buyer’s Power
10.2.3 Threat of New Entrants
10.2.4 Degree of Rivalry
10.2.5 Threat of Substitutes
10.3 EMR’s Key Indicators for Demand
10.4 EMR’s Key Indicators for Price
11 Competitive Landscape
11.1 Market Structure
11.2 Company Profiles
11.2.1 F. Hoffmann-La Roche Ltd.
11.2.1.1 Company Overview
11.2.1.2 Product Portfolio
11.2.1.3 Demographic Reach and Achievements
11.2.1.4 Certifications
11.2.2 Abbott Laboratories
11.2.2.1 Company Overview
11.2.2.2 Product Portfolio
11.2.2.3 Demographic Reach and Achievements
11.2.2.4 Certifications
11.2.3 Qiagen N.V
11.2.3.1 Company Overview
11.2.3.2 Product Portfolio
11.2.3.3 Demographic Reach and Achievements
11.2.3.4 Certifications
11.2.4 Thermo Fisher Scientific Inc.
11.2.4.1 Company Overview
11.2.4.2 Product Portfolio
11.2.4.3 Demographic Reach and Achievements
11.2.4.4 Certifications
11.2.5 Illumina Inc.
11.2.5.1 Company Overview
11.2.5.2 Product Portfolio
11.2.5.3 Demographic Reach and Achievements
11.2.5.4 Certifications
11.2.6 Bio-Rad Laboratories, Inc.
11.2.6.1 Company Overview
11.2.6.2 Product Portfolio
11.2.6.3 Demographic Reach and Achievements
11.2.6.4 Certifications
11.2.7 Others
12 Industry Events and Developments
List of Figures and Tables
1. Global Haemato Oncology Testing Market: Key Industry Highlights, 2016 and 2026
2. Global Haemato Oncology Testing Historical Market: Breakup by Cancer Type (USD Million), 2017-2021
3. Global Haemato Oncology Testing Market Forecast: Breakup by Cancer Type (USD Million), 2022-2027
4. Global Haemato Oncology Testing Historical Market: Breakup by Technology (USD Million), 2017-2021
5. Global Haemato Oncology Testing Market Forecast: Breakup by Technology (USD Million), 2022-2027
6. Global Haemato Oncology Testing Historical Market: Breakup by Application (USD Million), 2017-2021
7. Global Haemato Oncology Testing Market Forecast: Breakup by Application (USD Million), 2022-2027
8. Global Haemato Oncology Testing Historical Market: Breakup by Region (USD Million), 2017-2021
9. Global Haemato Oncology Testing Market Forecast: Breakup by Region (USD Million), 2022-2027
10. North America Haemato Oncology Testing Historical Market: Breakup by Country (USD Million), 2017-2021
11. North America Haemato Oncology Testing Market Forecast: Breakup by Country (USD Million), 2022-2027
12. Europe Haemato Oncology Testing Historical Market: Breakup by Country (USD Million), 2017-2021
13. Europe Haemato Oncology Testing Market Forecast: Breakup by Country (USD Million), 2022-2027
14. Asia Pacific Haemato Oncology Testing Historical Market: Breakup by Country (USD Million), 2017-2021
15. Asia Pacific Haemato Oncology Testing Market Forecast: Breakup by Country (USD Million), 2022-2027
16. Latin America Haemato Oncology Testing Historical Market: Breakup by Country (USD Million), 2017-2021
17. Latin America Haemato Oncology Testing Market Forecast: Breakup by Country (USD Million), 2022-2027
18. Middle East and Africa Haemato Oncology Testing Historical Market: Breakup by Country (USD Million), 2017-2021
19. Middle East and Africa Haemato Oncology Testing Market Forecast: Breakup by Country (USD Million), 2022-2027
20. Global Haemato Oncology Testing Market Structure
Key Questions Answered in the Report
In 2020, the global haemato oncology testing market attained a value of nearly USD 1.8 billion.
The market is projected to grow at a CAGR of 17% between 2021 and 2026.
The market is estimated to witness a healthy growth in the forecast period of 2022-2027 to reach about USD 4.6 billion by 2026.
The major drivers of the industry, such as the increasing prevalence of haematologic cancer, rising awareness regarding advanced therapies for cancer treatment and preference for personalised medical solutions, improving health care facilities, and the growing technological advancements, are expected to aid the market growth.
The key market trends guiding the growth of the industry include advancements in diagnostics and testing solutions, growing collaborations and R&D activities, and the development of real time assay kits.
The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.
Leukaemia, lymphoma, and Hodgkin lymphoma are the major cancer types to be treated using haemato oncology testing.
PCR, IHC, NGS, and cytogenetics, among others, are the significant haemato oncology testing technologies available in the market.
Clinical laboratories, hospitals, and academic and research institutes, among others, are the leading applications of the product in the industry.
The major players in the industry are F. Hoffmann-La Roche Ltd., Abbott, Qiagen, Thermo Fisher Scientific Inc., Illumina, Inc., Bio-Rad Laboratories, Inc., MolecularMD, ArcherDX, Inc., Arup Laboratories, and Asuragen, Inc., among others.
Analyst Review
The global haemato oncology testing market attained a value of USD 1.8 billion in 2020, driven by the rising incidences of haematologic cancer and the growing awareness regarding its treatment globally. Aided by the growing investment in the research and development activities, the market is expected to witness a further growth in the forecast period of 2022-2027, growing at a CAGR of 17%. The market is projected to reach USD 4.6 billion by 2026.
EMR’s meticulous research methodology delves deep into the market, covering the macro and micro aspects of the industry. Based on cancer types, the haemato oncology testing industry can be segmented into leukaemia, lymphoma, and Hodgkin lymphoma, among others. On the basis of technology, the industry is divided into PCR, IHC, NGS, and cytogenetics, among others. By application, the industry is categorised into clinical laboratories, hospitals, and academic and research institutes, among others. The major regional markets for haemato oncology testing are North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. The key players in the above market include F. Hoffmann-La Roche Ltd., Abbott, Qiagen, Thermo Fisher Scientific Inc., Illumina, Inc., Bio-Rad Laboratories, Inc., MolecularMD, ArcherDX, Inc., Arup Laboratories, Asuragen, Inc., and others.
EMR’s research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable, and help them remain ahead of their competition.
Purchase Options
Call us on
Purchase Full Report
Mini Report
$1499
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next UpdateSingle User License
$2699-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next UpdateFive User License
$3699-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$4699-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Contact AnalystAny Question? Speak With An Analyst
Request SampleView A Sample
Request CustomisationDid You Miss Anything, Ask Now
Why Expert Market Research?RIGHT PEOPLE
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
RIGHT METHODOLOGY
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
RIGHT PRICE
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
RIGHT SUPPORT
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
Similar Reports
The global veterinary diagnostic imaging market is driven by the growing prevalence of health-related issues in animals. Aided by the increasing use of veterinary diagnostic imaging in research activi...
The global urinalysis market attained a value of about USD 1.9 billion in 2020. The market is further expected to grow in the forecast period of 2022-2027 at a CAGR of 6.8% to reach nearly USD 2.8 bil...
The global dengue testing market stood at a value of around USD 456.2 million in 2020. The market is further expected to grow in the forecast period of 2022-2027 at a CAGR of 4.63% to reach USD 598.4 ...
The global clinical nutrition market attained a value of about USD 33.60 billion in 2020, driven by the rise in the prevalence of metabolic disorders. Aided by the high spending on healthcare and incr...
The global liquid biopsy market stood at a value of around USD 1,250 million in 2020. The market is further expected to grow at a CAGR of 22% in the forecast period of 2022-2027 to attain a value of U...
NEWSLETTER